<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00394121</url>
  </required_header>
  <id_info>
    <org_study_id>SKY2028-3-003</org_study_id>
    <nct_id>NCT00394121</nct_id>
  </id_info>
  <brief_title>New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma</brief_title>
  <official_title>Long-term Open-label Safety Study With SkyePharma FlutiForm HFA pMDI (100/10 µg and 250/10 µg) in Adult and Adolescent Patients With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SkyePharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SkyePharma AG</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety of the fixed combination asthma
      drug FlutiForm HFA MDI (containing fluticasone propionate and formoterol fumarate) in adult
      and adolescent patients with mild to moderate-severe asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term safety after twice daily treatment with FlutiForm HFA MDI over 12 months.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long-term efficacy after twice daily treatment with FlutiForm HFA MDI over 12 months.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate/formoterol fumarate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Ages eligible for study: 12 years and above; genders eligible for study: both; prior
        steroid use: steroid-requiring.

        Inclusion Criteria:

          -  History of asthma for at least 12 months.

          -  Documented use of inhaled corticosteriod for at least 4 weeks prior to Screening Visit
             Demonstrate FEV-1 of 40-80% of predicted normal values at Screening and Baseline
             Visit.

          -  Documented reversibility of 15% within 6 months of Screening Visit or at Screening
             Visit (15% increase from pre-FEV-1 levels following albuterol inhalation).

          -  Symptoms of Asthma during Run-in.

          -  Females of childbearing potential must have a negative urine pregnancy test at
             Screening and Baseline Visits. Females are eligible only if they are not pregnant or
             lactating and are either sterile or using acceptable methods of contraception.

          -  Must otherwise be healthy.

          -  Provide written informed consent. Wishes of minors must be respected.

        Exclusion Criteria:

          -  Life-threatening asthma within past year or during Run-in Period.

          -  History of systemic corticosteroid medication within 3 months before Screening Visit.

          -  History of omalizumab use within the past 6 months.

          -  History of leukotriene receptor antagonist use, e.g., montelukast, within the past
             week.

          -  Current evidence of history of any clinically significant disease or abnormality
             including uncontrolled hypertension, uncontrolled coronary artery disease, congestive
             heart failure, myocardial infarction, or cardiac dysrhythmia.

          -  Upper or lower respiratory infection within 4 weeks prior to Screening Visit or during
             Run-in Period.

          -  Significant, non-reversible, pulmonary disease (e.g., chronic obstructive pulmonary
             disease [COPD], cystic fibrosis, bronchiectasis).

          -  Known Human Immunodeficiency Virus (HIV)-positive status.

          -  Smoking history equivalent to &quot;10 pack years&quot;.

          -  Current smoking history within 12 months prior to Screening Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rudersdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Solingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kecskemet</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mosonmagyarovar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Carrickfergus</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chippenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Downpatrick</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heywood</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Solihull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sunbury on Thames</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Swindon Wilts</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2006</study_first_submitted>
  <study_first_submitted_qc>October 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2006</study_first_posted>
  <disposition_first_submitted>August 24, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 24, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 27, 2010</disposition_first_posted>
  <last_update_submitted>August 24, 2010</last_update_submitted>
  <last_update_submitted_qc>August 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2010</last_update_posted>
  <keyword>Asthma</keyword>
  <keyword>Fluticasone Propionate</keyword>
  <keyword>Formoterol Fumarate</keyword>
  <keyword>Pressurized metered does inhaler</keyword>
  <keyword>Hydrofluoroalkane</keyword>
  <keyword>Mild to moderate-severe asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

